Ask AI
HER2 Expression Spectrum: Module

CME

Spectrum of HER2 Expression and Its Clinical Implications in Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: January 08, 2024

Expiration: January 07, 2025

Activity

Progress
1
Course Completed

References

  1. Slamon D J, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
  2. Ran F, Liu Y, Wang C, et al. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem. 2022;229:114009.
  3. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105-2122.
  4. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610-621.
  5. Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-low paradigm in breast oncology: New standards, future horizons. Cancer Discov. 2022a;12:2026-2030.
  6. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  7. Marchio C, Annaratone L, Marques A, et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123-135.
  8. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41:3867-3872.
  9. Nitta H, Kelly BD, Padilla M, et al. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012;7:60.
  10. Kamangar E, Bishop J. Current challenges for HER2 immunohistochemistry testing in diagnostic pathology. health.ucdavis.edu/blog/lab-best-practice/current-challenges-for-her2-immunohistochemistry-testing-in-diagnostic-pathology/2019/05. Accessed December 28, 2023.
  11. Ivanova M, Porta FM, D'Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2023.
  12. Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8:1-4.
  13. Geukens T, De Schepper M, Richard F, et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur J Cancer. 2023;188:152-160.
  14. Tarantino P, Gandini S, Nicolo E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022b;163:35-43.
  15. Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7:137.
  16. Garrido-Castro AC, Ngo LD, Richardson ET, et al. Dynamics of HER2-low expression in triple-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium; 2022. Abstract HER2-10.
  17. Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023;67:116-123.
  18. Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: Pathological and clinical landscape. J Clin Oncol. 2020;38:1951-1962.
  19. Prat A, Modi S, Tsurutani J, et al. Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04. Presented at: San Antonio Breast Cancer Symposium; 2022. Abstract HER2-18.
  20. Dieras V, Deluche E, Lusque A, et al. Trastuzumab deruxtecan for advanced breast cancer patients, regardless of HER2 status: A phase II study with biomarkers analysis (DAISY). Presented at: San Antonio Breast Cancer Symposium; 2021. Abstracr PD8-02.
  21. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo Inc.; 2022.
  22. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2023.
  23. Meric-Bernstam F, Krop I, Juric D, et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor–positive/HER2–negative breast cancer (BC). Presented at: San Antonio Breast Cancer Symposium; 2022. Abstract PD13-08.
  24. Globerson Y. A fully automatic artificial intelligence system for accurate and reproducible HER2 IHC scoring in breast cancer. Presented at: San Antonio Breast Cancer Symposium; 2022. Abstract P6-04-05.
  25. Moutafi M, Robbins CJ, Yaghoobi V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest. 2022;102:1101-1108.
  26. Al Banyahyati B. A prospective approach for the evaluation of a one-step RT-qPCR based test for the quantification of HER2 protein in formalin-fixed and paraffin-embedded breast cancer tissues. Ann Oncol. 2020;30(S2):164P.
  27. Gustavson M, Haneder S, Spitzmueller A, et al. Novel approach to HER2 quantification: Digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. Presented at: San Antonio Breast Cancer Symposium; 2020. Abstract PD6-01.
  28. Corgiat BA, O'Shaughnessy J, LoRusso P, et al. Novel quantitative HER2 assay for determining dynamic HER2 expression in the HER2 IHC 0 “ultra-low” setting: Implications for precision therapy in HER2- breast cancer. Presented at: San Antonio Breast Cancer Symposium; 2022. Abstract HER2-17.